$9.41
1.29% today
Nasdaq, Feb 28, 05:49 pm CET
ISIN
IL0011407140
Symbol
URGN
Sector
Industry

UroGen Pharma Ltd. Stock price

$9.29
-1.19 11.36% 1M
-4.98 34.90% 6M
-1.36 12.77% YTD
-9.30 50.03% 1Y
+3.29 54.83% 3Y
-17.48 65.30% 5Y
-4.69 33.55% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-0.07 0.75%
ISIN
IL0011407140
Symbol
URGN
Sector
Industry

Key metrics

Market capitalization $392.03m
Enterprise Value $264.13m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.96
P/S ratio (TTM) P/S ratio 4.39
P/B ratio (TTM) P/B ratio 15.36
Revenue growth (TTM) Revenue growth 15.64%
Revenue (TTM) Revenue $89.36m
EBIT (operating result TTM) EBIT $-83.73m
Free Cash Flow (TTM) Free Cash Flow $-95.37m
Cash position $250.65m
EPS (TTM) EPS $-3.14
P/E forward negative
P/S forward 4.31
EV/Sales forward 2.90
Short interest 14.94%
Show more

Is UroGen Pharma Ltd. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

UroGen Pharma Ltd. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a UroGen Pharma Ltd. forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a UroGen Pharma Ltd. forecast:

Buy
86%
Hold
14%

Financial data from UroGen Pharma Ltd.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
89 89
16% 16%
100%
- Direct Costs 8.70 8.70
7% 7%
10%
81 81
19% 19%
90%
- Selling and Administrative Expenses 110 110
24% 24%
123%
- Research and Development Expense 54 54
10% 10%
60%
-82 -82
19% 19%
-92%
- Depreciation and Amortization 1.30 1.30
25% 25%
1%
EBIT (Operating Income) EBIT -84 -84
18% 18%
-94%
Net Profit -115 -115
10% 10%
-129%

In millions USD.

Don't miss a Thing! We will send you all news about UroGen Pharma Ltd. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

UroGen Pharma Ltd. Stock News

Neutral
Business Wire
one day ago
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report fourth quarter and full-year 2024 financial results on Monday, March 10, 2025, prior to the open of the stock market. The announcement will be followed by a live au...
Neutral
Business Wire
4 days ago
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference to take place on March 3-5, 2025. TD Cowen 45th Annual Health Care Conference Date / Time...
Neutral
Business Wire
8 days ago
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced expansion of its oncology pipeline portfolio through the acquisition of assets relating to a next-generation oncolytic virus ICVB-1042 from IconOVir Bio, Inc. (IconOVir). In addition, ...
More UroGen Pharma Ltd. News

Company Profile

UroGen Pharma Ltd. is a clinical stage pharmaceutical company, which engages in the provision of non-surgical and localized solutions for urological pathologies to address a clinical unmet need in field of uro-oncology. Its pipeline includes upper tract urothelial carcinoma, low grade non muscle invasive bladder cancer, carcinoma in situ of the bladder, and overactive bladder. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ.

Head office Israel
CEO Elizabeth Barrett
Employees 201
Founded 2004
Website www.urogen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today